Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study

制定B型钠尿肽(BNP)水平≥100 pg/ml的风险评分:suita研究

阅读:1

Abstract

BACKGROUND: Increased plasma levels of B-type natriuretic peptide (BNP) serve as a biomarker for heart failure (HF). This study aimed to develop a risk score to predict elevated BNP levels using traditional cardiovascular disease (CVD) risk factors. METHODS AND RESULTS: We analyzed data from 2809 Japanese individuals aged ≥ 40 years from the Suita Study, a population-based prospective cohort. All participants underwent follow-ups involving BNP measurements every two years. Developing BNP levels ≥ 100 pg/mL, a potential indicator of HF requiring treatment, was the outcome. Cox regression was applied to calculate hazard ratios for several CVD risk factors associated with developing BNP levels ≥ 100 pg/mL. Within a median follow-up period of 8 years, 339 participants developed BNP levels ≥ 100 pg/mL. The risk factors included older age, heavy smoking, former and heavy alcohol consumption, high blood pressure, estimated glomerular filtration rate < 45 mL/min/1.73 m(2), CVD history, cardiac murmur, arrhythmia including atrial fibrillation, and left ventricular hypertrophy. The prediction model performed well in terms of discrimination (C-statistics = 0.750) and calibration (p-value for goodness-of-fit > 0.150). CONCLUSION: Our findings highlighted several CVD risk factors for BNP levels ≥ 100 pg/mL in the general Japanese population. Lifestyle modifications and regular health check-ups should be applied to reduce HF risk in vulnerable individuals.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。